ライフサイエンスコーパス: pulmonary tuberculosis

1 tained during nine years from a patient with pulmonary tuberculosis.

2 ed BCG has inefficient effectiveness against pulmonary tuberculosis.

3 osed cases), and bacteriologically confirmed pulmonary tuberculosis.

4 there is no effective vaccine against adult pulmonary tuberculosis.

5 V (CD4 cell counts </=125 cells per muL) and pulmonary tuberculosis.

6 specimens in 3640 children investigated for pulmonary tuberculosis.

7 rom 17 Ugandans treated for drug-susceptible pulmonary tuberculosis.

8 sociated with an increased susceptibility to pulmonary tuberculosis.

9 n Themis(I23N) mice causes susceptibility to pulmonary tuberculosis.

10 ning regimen for treating rifampin-sensitive pulmonary tuberculosis.

11 clinical treatment outcomes in patients with pulmonary tuberculosis.

12 atients with newly diagnosed sputum-positive pulmonary tuberculosis.

13 ry efficacy outcomes were death and incident pulmonary tuberculosis.

14 ed their critical role in protection against pulmonary tuberculosis.

15 l for PMN-driven destructive inflammation in pulmonary tuberculosis.

16 h treatment of uncomplicated, smear-positive pulmonary tuberculosis.

17 n 370 patients with microbiologically proven pulmonary tuberculosis.

18 r suspected drug-resistant or HIV-associated pulmonary tuberculosis.

19 tiveness of corticosteroids in patients with pulmonary tuberculosis.

20 school in the United Kingdom presented with pulmonary tuberculosis.

21 ust to exclusion of individuals experiencing pulmonary tuberculosis.

22 g PD-1 and its ligand(s) among patients with pulmonary tuberculosis.

23 ied 41 eligible trials, 18 of which assessed pulmonary tuberculosis.

24 r the response to treatment in patients with pulmonary tuberculosis.

25 ciated with increased mortality and incident pulmonary tuberculosis.

26 icroscopy for diagnosis of culture-confirmed pulmonary tuberculosis.

27 ing host T-cell function among patients with pulmonary tuberculosis.

28 ity for all forms of tuberculosis, including pulmonary tuberculosis.

29 om HIV-negative patients suspected of having pulmonary tuberculosis.

30 urable in exhaled breath in individuals with pulmonary tuberculosis.

31 eolar lavage cells from patients with active pulmonary tuberculosis.

32 es that had either tuberculous meningitis or pulmonary tuberculosis.

33 occur at extrapulmonary sites without active pulmonary tuberculosis.

34 is (EPTB) has increased relative to cases of pulmonary tuberculosis.

35 ents receiving intensive-phase treatment for pulmonary tuberculosis.

36 ted to identify most children with confirmed pulmonary tuberculosis.

37 MMP inhibitors as adjunctive treatments for pulmonary tuberculosis.

38 ve phenotypes of latent infection and active pulmonary tuberculosis.

39 esearch on the microbiome's association with pulmonary tuberculosis.

40 inamide in the first 8 weeks of treatment of pulmonary tuberculosis.

41 nexposed control subjects, and patients with pulmonary tuberculosis.

42 of two of these regimens in a mouse model of pulmonary tuberculosis.

43 ates with bacteria in lungs of patients with pulmonary tuberculosis.

44 fferences in mortality attributed to HIV and pulmonary tuberculosis.

45 of-care assay as a screening tool for active pulmonary tuberculosis.

46 nostic performance of laboratory testing for pulmonary tuberculosis.

47 haran Africa is not as well described as for pulmonary tuberculosis.

48 ion (1.29, 1.10-1.50; p=0.001), a history of pulmonary tuberculosis (1.20, 1.07-1.34; p=0.002), modif

49 25 (43%) children had pulmonary tuberculosis, 24 (41%) had extrapulmonary tube

50 Among 236 patients with pulmonary tuberculosis, 59 (25%) had isoniazid resistanc

51 One hundred patients with pulmonary tuberculosis (65% human immunodeficiency virus

52 Pulmonary tuberculosis, a disease caused by Mycobacteriu

53 Air pollution and pulmonary tuberculosis: a nested case-control study amon

54 dently associated with household exposure to pulmonary tuberculosis (adjusted RR [aRR], 4.75 [95% con

55 or risk factor for the development of active pulmonary tuberculosis, although the immunological mecha

56 smear positive or culture positive, or both) pulmonary tuberculosis among adults (aged >/=15 years) i

57 on on the risk of mortality and incidence of pulmonary tuberculosis among adults initiating antiretro

58 he prevalence of microbiologically confirmed pulmonary tuberculosis among persons 15 years of age or

59 We identified 18 trials reporting pulmonary tuberculosis and 6 reporting miliary or mening

60 Among 200 patients with pulmonary tuberculosis and 88 controls, FENO was lower f

61 cted an association study in Morocco between pulmonary tuberculosis and a panel of single-nucleotide

62 t study of HIV-infected patients with active pulmonary tuberculosis and baseline CD4 counts </=125 ce

63 us (HIV) positive and negative patients with pulmonary tuberculosis and controls.

64 ases including pneumonia with pleural fluid, pulmonary tuberculosis and healthy people as controls.

65 In 2011-14, pulmonary tuberculosis and HIV were responsible for 84.9

66 Reductions in pulmonary tuberculosis and HIV-related mortality account

67 Cachexia is a hallmark of pulmonary tuberculosis and is associated with poor progn

68 backgrounds reproduce a clinical spectrum of pulmonary tuberculosis and may be used to more accuratel

69 assay with GLA samples for the detection of pulmonary tuberculosis and MDR tuberculosis in new paedi

70 is associated with an increased incidence of pulmonary tuberculosis and mortality among people living

71 D sufficiency may decrease the incidence of pulmonary tuberculosis and other infectious diseases.

72 sociated with higher efficacy of BCG against pulmonary tuberculosis and possibly against miliary and

73 ks of ART and early mortality in adults with pulmonary tuberculosis and pre-ART CD4 counts </= 125 ce

74 No particular link was found between pulmonary tuberculosis and pulmonary embolism, or betwee

75 depleted from the blood of participants with pulmonary tuberculosis and restored upon treatment.

76 RIF (Xpert) with microscopy for detection of pulmonary tuberculosis and rifampicin resistance in chil

77 Index patient predictors were pulmonary tuberculosis and sputum smear grade, age, and

78 criteria in children with culture-confirmed pulmonary tuberculosis and those in whom tuberculosis ha

79 ociated with both tuberculous meningitis and pulmonary tuberculosis and were strongest with a recessi

80 8.1%) were HIV-infected, 40% had concomitant pulmonary tuberculosis, and 14.7% died within 12 months

81 c testing for latent tuberculosis infection, pulmonary tuberculosis, and extrapulmonary tuberculosis

82 the incidence of microbiologically confirmed pulmonary tuberculosis, and new cases of pulmonary tuber

83 People with pulmonary tuberculosis are at risk of developing chronic

84 United States, individuals with presumptive pulmonary tuberculosis are placed in airborne infection

85 rated from the cough of patients with active pulmonary tuberculosis are the source of MTB infection.

86 cell subsets that appear in the lung during pulmonary tuberculosis are unknown.

87 -vitro hollow fibre model of infection using pulmonary tuberculosis as a paradigm.

88 s exposed to Mtb rapidly progressed to acute pulmonary tuberculosis as indicated by worsening clinica

89 s in the control group (226 per 100,000) had pulmonary tuberculosis, as confirmed by a positive nucle

90 ssifiable including 21 (21.0%) with definite pulmonary tuberculosis, as they did not meet the NIH cri

91 enrolled close contacts of individuals with pulmonary tuberculosis, assessed LTBI status, and determ

92 In Papua, we measured FENO in patients with pulmonary tuberculosis at baseline and serially over 6 m

93 n 28 of 29 (97%) cases with culture-positive pulmonary tuberculosis at bedaquiline initiation.

94 8 controls, FENO was lower for patients with pulmonary tuberculosis at diagnosis (geometric mean FENO

95 st 18 years with microbiologically confirmed pulmonary tuberculosis at Old Mulago Hospital (Kampala,

96 ts diagnosed with or receiving treatment for pulmonary tuberculosis at randomisation, or suspected to

97 <25 years) with an odds ratio of developing pulmonary tuberculosis at rs897200 for GG vs AG/AA subje

98 m of patients with microscopy smear-positive pulmonary tuberculosis-at eight sites in South Africa an

99 m, MA, USA) for screening for HIV-associated pulmonary tuberculosis before antiretroviral therapy (AR

100 so no difference in the overall incidence of pulmonary tuberculosis between the vitamin D(3) (50 even

101 stimate VE against all tuberculosis and just pulmonary tuberculosis by time since vaccination, adjust

102 first evidence relating arsenic exposure to pulmonary tuberculosis, by estimating mortality rate rat

103 dinal cohort of household contacts (HHCs) of pulmonary tuberculosis case patients in Lima, Peru.

104 , a patient with microbiologically confirmed pulmonary tuberculosis (Case 2).

105 Of 12 culture-confirmed pulmonary tuberculosis cases identified among children w

106 A substantial proportion of active pulmonary tuberculosis cases in countries where tubercul

107 tified 8 (42.1%) of the 19 culture-confirmed pulmonary tuberculosis cases that were identified throug

108 Twenty-seven (3.0%) culture-confirmed pulmonary tuberculosis cases were identified among 906 c

109 e and 101 (0.3%) bacteriologically confirmed pulmonary tuberculosis cases.

110 were measured in 45 patients with confirmed pulmonary tuberculosis (cases), 47 tuberculin skin test

111 stered BCG confers robust protection against pulmonary tuberculosis challenge.

112 wian adults with microbiologically confirmed pulmonary tuberculosis, clinical and laboratory paramete

113 e of sputum Mtb clearance over 16 wk in this pulmonary tuberculosis cohort.

114 ay samples from HIV-1-infected patients with pulmonary tuberculosis compared with those with non-tube

115 nificantly greater association with incident pulmonary tuberculosis, compared with vitamin D sufficie

116 Inclusion patients were those with pulmonary tuberculosis confirmed by sputum smear microsc

117 tion of tests for the diagnosis of childhood pulmonary tuberculosis (CPTB) is complicated by the abse

118 men were also elevated but with fewer excess pulmonary tuberculosis deaths (359 among men and 95 amon

119 ntly with tofacitinib than with placebo, and pulmonary tuberculosis developed in two patients in the

120 older than 15 years of age) who had incident pulmonary tuberculosis diagnosed at any of 106 public he

121 Bangladesh; aged >15 years in Pakistan) with pulmonary tuberculosis diagnosed in the previous 4 weeks

122 he efficacy of M72/AS01(E) to prevent active pulmonary tuberculosis disease according to the first ca

123 nucleic acid amplification testing (MTD) for pulmonary tuberculosis disease diagnosis in the United S

124 d provided protection against progression to pulmonary tuberculosis disease for at least 3 years.

125 ntent-to-treat trial in 199 individuals with pulmonary tuberculosis disease in Tbilisi, Georgia.

126 ine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety c

127 ere household contacts of adults with active pulmonary tuberculosis disease.

128 tation improves outcomes in individuals with pulmonary tuberculosis disease.

129 a standard regimen of ATT for drug-sensitive pulmonary tuberculosis (DS-PTB).

130 cohort study of inpatients with presumptive pulmonary tuberculosis enrolled adults with 1 or more sp

131 rease the yield of microscopy for diagnosing pulmonary tuberculosis, even in high-HIV-prevalence sett

132 00 patients with previous history of treated pulmonary tuberculosis, excluding those with active pulm

133 adults with human immunodeficiency virus and pulmonary tuberculosis experienced meaningful declines i

134 ousehold as an active case of smear-positive pulmonary tuberculosis exposed to M. africanum progress

135 ntified cases of microbiologically confirmed pulmonary tuberculosis from 2004 to 2012 from the Nation

136 ith drug-susceptible or rifampicin-resistant pulmonary tuberculosis from seven sites in South Africa,

137 s with primary and secondary cases of active pulmonary tuberculosis from the southern region (Afghani

138 ture media, from participants with suspected pulmonary tuberculosis from the United States, Brazil, a

139 ted tuberculosis (group 3); 49 patients with pulmonary tuberculosis (group 4); and 48 healthy control

140 netic epidemiological evidence suggests that pulmonary tuberculosis has a strong human genetic compon

141 estimates, the prevalence of smear-positive pulmonary tuberculosis has decreased by 26.4% (from 231

142 he prevalence of bacteriologically confirmed pulmonary tuberculosis has increased by 17.8% (from 365

143 iagnosis of culture-proven, drug-susceptible pulmonary tuberculosis immediately prior to treatment an

144 Among patients with pulmonary tuberculosis, impaired pulmonary NO bioavailab

145 t of reported patients with suspected active pulmonary tuberculosis in 2008-2010 from Georgia, Hawaii

146 ng adult patients treated for smear-positive pulmonary tuberculosis in 70 clinics across Vietnam.

147 to detect and treat all infectious cases of pulmonary tuberculosis in a timely fashion, allowing con

148 come was the prevalence of culture-confirmed pulmonary tuberculosis in adults (>/=18 years), defined

149 ed retrospectively a cohort of patients with pulmonary tuberculosis in Birmingham, United Kingdom (Ja

150 ecutive children hospitalized with suspected pulmonary tuberculosis in Cape Town, South Africa, who w

151 fers better sensitivity for the diagnosis of pulmonary tuberculosis in children and its scale-up will

152 ia for standardized diagnostic categories of pulmonary tuberculosis in children have not been validat

153 Rationale: Microbiological confirmation of pulmonary tuberculosis in children is desirable.Objectiv

154 Rapid and accurate diagnosis of pulmonary tuberculosis in children remains challenging b

155 e and specific method for rapid diagnosis of pulmonary tuberculosis in children who cannot produce sp

156 compared with microscopy in the diagnosis of pulmonary tuberculosis in children.

157 he most widely available diagnostic test for pulmonary tuberculosis in countries with a high burden o

158 ositive, rifampin-sensitive, newly diagnosed pulmonary tuberculosis in five sub-Saharan African count

159 mains the optimal sample type for diagnosing pulmonary tuberculosis in HIV-negative patients with the

160 locus sst1 that controls the progression of pulmonary tuberculosis in immunocompetent hosts.

161 tamin D in adults with sputum smear-positive pulmonary tuberculosis in London, UK.

162 ted incidence of bacteriologically confirmed pulmonary tuberculosis in migrants screened before entry

163 Placing inpatients with presumed active pulmonary tuberculosis in respiratory isolation pending

164 the incidence of microbiologically confirmed pulmonary tuberculosis in South Africa had declined by 2

165 amples from 2,406 individuals with suspected pulmonary tuberculosis in South Africa were tested by Xp

166 ould improve the assessment of the burden of pulmonary tuberculosis in South Africa.

167 , Vietnam, resulted in a lower prevalence of pulmonary tuberculosis in the fourth year than standard

168 We assessed the prevalence of pulmonary tuberculosis in the Xinjiang province, China,

169 blish the mortality rate among patients with pulmonary tuberculosis in Vietnam and to quantify the ex

170 s in other parts of China, the prevalence of pulmonary tuberculosis in Xinjiang remains high.

171 is confirmed, were excluded from analyses of pulmonary tuberculosis incidence.

172 ets that examined clinical cohorts of active pulmonary tuberculosis infection in whole blood.

173 C, human immunodeficiency virus, and active pulmonary tuberculosis is considered.

174 performance of laboratory tests to diagnose pulmonary tuberculosis is dependent on the quality of th

175 Active pulmonary tuberculosis is difficult to diagnose and trea

176 Isolation of patients suspected for pulmonary tuberculosis is guided by serial sputum smears

177 A hallmark of pulmonary tuberculosis is the formation of macrophage-ri

178 m tuberculosis (MTB), the causative agent of pulmonary tuberculosis, is difficult to eliminate by ant

179 e current standard care for drug-susceptible pulmonary tuberculosis, isoniazid, rifampicin, PZA, and

180 Development of a vaccine against pulmonary tuberculosis may require immunization strategi

181 Eight participants with active pulmonary tuberculosis (mean age, 48.1 years; age range,

182 In pulmonary tuberculosis, MMP-driven immunopathology gener

183 case definition (bacteriologically confirmed pulmonary tuberculosis not associated with human immunod

184 The new smear-positive pulmonary tuberculosis notification rate in 2011 in Xinj

185 al evaluation enrolled adults with suspected pulmonary tuberculosis, obtained three sputum samples fr

186 ve men, compared with incidence rates of new pulmonary tuberculosis of 3.7 cases per 100 PYAR (95% CI

187 ic in Montreal, Canada, for the detection of pulmonary tuberculosis on induced sputum samples, using

188 ciation was stronger among younger subjects (pulmonary tuberculosis onset <25 years) with an odds rat

189 d treatment programmes for the prevention of pulmonary tuberculosis or mortality.

190 (T-SPOT) among adults with suspected active pulmonary tuberculosis or patients with confirmed cases

191 dependently associated with the incidence of pulmonary tuberculosis (P < .001), severe anemia (P < .0

192 ia (P = 0.002), oral thrush (P = 0.007), and pulmonary tuberculosis (P < 0.001) but not change in CD4

193 ed sample, 6 STAT4 SNPs were associated with pulmonary tuberculosis (P = .0013-.01).

194 study of children who were close contacts of pulmonary tuberculosis patients in Indonesia from August

195 Ex vivo blood samples from 27 pulmonary tuberculosis patients were assayed at diagnosi

196 rent clinical forms of tuberculosis, such as pulmonary tuberculosis, pleural tuberculosis, and lymph

197 fatal chronic obstructive pulmonary disease, pulmonary tuberculosis, pneumonia, or lung cancer).

198 In each age group and sex, the pulmonary tuberculosis prevalence was higher in the 2010

199 agnostic accuracy of Xpert MTB/RIF assay for pulmonary tuberculosis (PTB) and extrapulmonary TB (EPTB

200 in up to 40% of individuals co-infected with pulmonary tuberculosis (PTB) and HIV, primarily upon ant

201 rculosis (8,162 cases and 277,643 controls), pulmonary tuberculosis (PTB) and M. tuberculosis infecti

202 of adjunctive vitamin D in the treatment of pulmonary tuberculosis (PTB) are variously limited by sm

203 ert testing from 115 children with suspected pulmonary tuberculosis (PTB) detected 8/17 (47%) culture

204 Pulmonary tuberculosis (PTB) has clinically significant

205 ely used laboratory diagnostic technique for Pulmonary Tuberculosis (PTB) in low-and-middle income co

206 ortion of participants with culture-positive pulmonary tuberculosis (PTB) initiated on appropriate TB

207 Pulmonary tuberculosis (PTB) is one of the major health

208 Previous pulmonary tuberculosis (PTB) or lower respiratory tract

209 Clinically diagnosed pulmonary tuberculosis (PTB) patients lack microbiologic

210 A rapid diagnosis of pediatric pulmonary tuberculosis (PTB) using Xpert MTB/RIF (Mycoba

211 d the development of new approaches to treat pulmonary tuberculosis (PTB).

212 ned against sera from patients infected with pulmonary tuberculosis (PTB).

213 den and delayed sputum culture conversion in pulmonary tuberculosis (PTB).

214 f disease extent and mycobacterial burden in pulmonary tuberculosis (PTB).

215 olation (AII) of inpatients with presumptive pulmonary tuberculosis (PTB).

216 filum terminale of the spinal cord); and (2) pulmonary tuberculosis (PTB).

217 n immunodeficiency virus (HIV) infection and pulmonary tuberculosis (PTB).

218 Recurrent pulmonary tuberculosis rates >2 years after the first ep

219 presentation of microbiologically-confirmed pulmonary tuberculosis received standard 6-month first-l

220 Adults with pulmonary tuberculosis received standard 6-month therapy

221 ts with culture-confirmed, drug-susceptible, pulmonary tuberculosis receiving standard 4-drug therapy

222 a history of previously treated pleural and pulmonary tuberculosis referred to our hospital for ches

223 6-year-old HIV-seronegative patient with XDR pulmonary tuberculosis refractory to medical therapy.

224 ART service were systematically screened for pulmonary tuberculosis regardless of symptoms by testing

225 ion clusters (subcommunes) were screened for pulmonary tuberculosis, regardless of symptoms, annually

226 med pulmonary tuberculosis, and new cases of pulmonary tuberculosis registered for treatment, nationa

227 Of the 184 cases of pulmonary tuberculosis reported during the study period,

228 in mouse models of neuroinflammation and of pulmonary tuberculosis, respectively.

229 re treatment from Gambians and Ugandans with pulmonary tuberculosis, revealed by positive results of

230 cal end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a Wo

231 ween fractional exhale NO (FENO) and initial pulmonary tuberculosis severity, change during treatment

232 s with the ones from the 2010 China national pulmonary tuberculosis survey and the ones from a provin

233 irst, a patient presenting with 2-3 weeks of pulmonary tuberculosis symptoms (Case 1); and second, a

234 tic accuracy study, we recruited adults with pulmonary tuberculosis symptoms presenting at primary he

235 Diabetes mellitus (DM) increases risk for pulmonary tuberculosis (TB) and adverse treatment outcom

236 Mycobacterium tuberculosis causes pulmonary tuberculosis (TB) and claims 1.8 million human

237 Coexistence of pulmonary tuberculosis (TB) and lung cancer in clinic po

238 Although studies identified signatures for pulmonary tuberculosis (TB) and transcripts that predict

239 All active pulmonary tuberculosis (TB) cases newly diagnosed betwee

240 Close contacts of persons with pulmonary tuberculosis (TB) have high rates of TB diseas

241 A prediction model of prevalent pulmonary tuberculosis (TB) in HIV negative/unknown indi

242 agents associated with presumptive clinical pulmonary tuberculosis (TB) in Nigeria and evaluated the

243 Treatment failure after therapy of pulmonary tuberculosis (TB) infections is an important c

244 Microbiological diagnosis of pediatric pulmonary tuberculosis (TB) is challenging due to the di

245 Pulmonary tuberculosis (TB) is characterized by oxidativ

246 A hallmark of pulmonary tuberculosis (TB) is the formation of granulom

247 in human necrotic, nonnecrotic, and cavitary pulmonary tuberculosis (TB) lesions.

248 om HIV-negative, smear- and culture-positive pulmonary tuberculosis (TB) patients for the presence of

249 ease assays (IGRA), after close contact with pulmonary tuberculosis (TB) patients has not been extens

250 terial load prior to and during treatment in pulmonary tuberculosis (TB) patients.

251 Patients with pulmonary tuberculosis (TB) underwent a standard evaluat

252 Diagnosis of pulmonary tuberculosis (TB) usually includes laboratory

253 cination induces variable protection against pulmonary tuberculosis (TB), and a more effective TB vac

254 human immunodeficiency virus (HIV) who have pulmonary tuberculosis (TB), but its effects on the lung

255 cterium tuberculosis, the causative agent of pulmonary tuberculosis (TB), is responsible for millions

256 By using a murine model of pulmonary tuberculosis (TB), we have investigated whethe

257 st commonly used laboratory test to diagnose pulmonary tuberculosis (TB).

258 e of B cells in host defense against primary pulmonary tuberculosis (TB).

259 graphy (CXR) to screen and triage people for pulmonary tuberculosis (TB).

260 tuberculosis (MTb) is the causative agent of pulmonary tuberculosis (TB).

261 A sensitivity analysis in pulmonary tuberculosis that excluded trials with high po

262 radermally and has variable efficacy against pulmonary tuberculosis, the major cause of mortality and

263 t, in human subjects, previously treated for pulmonary tuberculosis, the MTB-containing CD271(+) BM-M

264 In a well-established BALB/c mouse model of pulmonary tuberculosis, the nanoparticles provided impro

265 ol trials (RCTs) that reported on first-line pulmonary tuberculosis therapy between June 2008 and Mar

266 intermittent dosing schedules in first-line pulmonary tuberculosis therapy.

267 m 755 HIV-uninfected adults with presumptive pulmonary tuberculosis to measure IgG antibody responses

268 riptional profiles in pulmonary sarcoidosis, pulmonary tuberculosis, to community acquired pneumonia

269 imicrobial activity of daily rifapentine for pulmonary tuberculosis treatment.

270 tine vs rifampin during the first 8 weeks of pulmonary tuberculosis treatment.

271 VE against pulmonary tuberculosis up to 9 years (excluding tubercul

272 fied in pretreatment sputum of patients with pulmonary tuberculosis using FDA microscopy, culture, an

273 e meta-regression indicated efficacy against pulmonary tuberculosis varied according to 3 characteris

274 iated with different sites of infection (eg, pulmonary tuberculosis versus extrapulmonary tuberculosi

275 The weighted prevalence of smear-positive pulmonary tuberculosis was 170 (95% CI 103-233) per 100

276 00 people and of bacteriologically confirmed pulmonary tuberculosis was 430 (249-611) per 100 000 peo

277 onstudy attending physicians requested GA if pulmonary tuberculosis was clinically suspected.

278 Active pulmonary tuberculosis was diagnosed in the United State

279 CASE REPORT: A young woman with pulmonary tuberculosis was found to have disseminated tu

280 Among 2140 patients in whom pulmonary tuberculosis was suspected, 799 (37%) were M.

281 pecimen from each person suspected of having pulmonary tuberculosis was tested by smear microscopy, d

282 Adults with sputum smear-positive pulmonary tuberculosis were assigned rifapentine 10, 15,

283 African children hospitalized with suspected pulmonary tuberculosis were enrolled.Measurements and Ma

284 lmonary tuberculosis relative to exclusively pulmonary tuberculosis were greater for Euro-American (a

285 Adults suffering from their first episode of pulmonary tuberculosis were identified in Kampala, Ugand

286 creened, 444 (28%) culture-positive cases of pulmonary tuberculosis were identified.

287 d adults with newly diagnosed smear-positive pulmonary tuberculosis were randomized to receive a 3- o

288 t-naive, sputum smear-positive patients with pulmonary tuberculosis were randomized to receive combin

289 total, 531 adults with sputum smear-positive pulmonary tuberculosis were randomized to rifapentine 10

290 , rifampicin-sensitive, previously untreated pulmonary tuberculosis were randomly assigned in a 1:1:1

291 523 371 cases of microbiologically confirmed pulmonary tuberculosis were recorded nationally.

292 Patients with an initial episode of pulmonary tuberculosis were recruited in South Africa.

293 of the 41 trials (including 13 of those for pulmonary tuberculosis) were done before the introductio

294 s aged 15 years or older of index cases with pulmonary tuberculosis who lived in desert shanty towns

295 least 16 years with active pulmonary or non-pulmonary tuberculosis who were eligible for DOT accordi

296 patients receiving antimicrobial therapy for pulmonary tuberculosis who were randomized to receive ad

297 ratory data were collected on 89 patients of pulmonary tuberculosis who were treated at our hospital

298 atment-naive patients with drug-susceptible, pulmonary tuberculosis, who were randomly assigned by co

299 oroccan population support an association of pulmonary tuberculosis with STAT4 promoter-region polymo

300 with newly diagnosed, rifampicin-susceptible pulmonary tuberculosis, with and without HIV, enrolled i